Drug Trial Radar · NCT07776210
Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 8, 2026
Primary completion
Mar 31, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Regenerative Ocular Immunobiologics LLCIndustry
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, multicenter, randomized, double-masked, vehicle-controlled, parallel-group clinical trial designed to evaluate the efficacy, safety, and tolerability of d-MAPPS™ Ophthalmic Solution in adult subjects with chronic ocular graft-versus-host disease (oGVHD). Eligible subjects will receive masked study treatment for 90 days, with the primary efficacy assessment performed at the Day 90 study visit.
Conditions
- oGVHD
- Ocular Graft Versus Host Disease
Interventions
d-MAPPS™ Ophthalmic SolutionBiological
Sterile, preservative-free ophthalmic solution administered as two drops into each eye four times daily for 90 consecutive days.
Matching vehicle controlBiological
Matching vehicle control supplied in identical masked containers and administered as two drops into each eye four times daily for 90 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Day 90 in Modified Oxford Corneal Staining ScoreTime frame: Baseline to Day 90 (±5 days)
- Change From Baseline to Day 90 in Ocular Surface Disease Index (OSDI) Total ScoreTime frame: Baseline to Day 90 (±5 days)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Beverly Hills Institute of Ophthalmology
Beverly Hills, California · Recruiting
Beverly Hills Optometry
Beverly Hills, California · Recruiting
Regenerative Ocular Immunobiologics, LLC.
Palm Harbor, Florida · Not yet recruiting
Eyewell, LLC.
Boston, Massachusetts · Recruiting
BostonSight
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.